Beyondspring (BYSI) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
SEED Therapeutics has announced a strategic research collaboration with Eisai Co., Ltd. to develop molecular glue degraders targeting neurodegenerative diseases and cancer, with potential payments up to $1.5 billion plus royalties. Additionally, SEED has initiated a Series A-3 financing round, led by Eisai, raising $24 million to advance their cancer treatment programs and expand their Targeted Protein Degradation (TPD) platform. This move strengthens SEED’s position in developing treatments for diseases with limited options and showcases their growth in the biotech sector, bolstered by prior investments from Eli Lilly and BeyondSpring.
For further insights into BYSI stock, check out TipRanks’ Stock Analysis page.